-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Humacyte, Lowers Price Target to $14

Benzinga·05/14/2025 13:48:25
Listen to the news
Benchmark analyst Bruce Jackson maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $17 to $14.